

Therapeutic targets in lymphoma

What is this work about?

The team is dedicated to the characterization of new therapeutic targets in aggressive B-cell lymphoma. The final objective of their work is the **design of individualized therapies**, as it is intended that the information obtained can serve for the conduct of phase I/II clinical trials, in partnership with the biotechnology companies and the hematology departments associated to their projects.

What problem did they face?

A large amount of data from several gene expression analysis techniques and tumor groups was gathered.

To identify the best genetic biomarkers to classify the different groups, they needed **to automatically integrate all these data sets**.

This integrative approach was not easily available in the classical analysis software tools, at least in an efficient manner.

Which was the contribution of AutoDiscovery ?


AutoDiscovery helped them **to unveil gene signatures** with high biological and clinic significance in their cancer models thanks to the following features:

- 👍 The **automatic consolidation** of the tumoral evolution and gene expression data.
- 👍 The exhaustive evaluation of relationships **within the different tumor groups**.
- 👍 The **Hypo Booster tool** to explore the factors underlying the evolution of tumoral volume and morphology.

Our collaborator

Gaël Roue  
PhD

Tenure-Track Investigator
Hemato-Oncology Area



SS-3



Success Case Sheet